RALEIGH, NC – Arbor Pharmaceuticals, a specialty pharmaceutical company focused on pediatric medicine, has closed a Series A round in an undisclosed amount.

Several new unidentified investors in addition to the company’s original investment group participated in the round.

The company says latest round of investment capital will support the launch of Arbor’s third product and facilitate continued growth of the company and its current and pipeline products.

In addition to completing the Series A financing Arbor has recently deployed a specialty sales force focused on promoting the company’s products to pediatricians across the United States.

The company says it plans to expand its sales force in coming months.

Since the founding of Arbor in 2006 the company has launched two novel prescription products for ear infections (ZINOTIC and NEOTIC) and is developing a pipeline of unique nonantibiotic products for common pediatric illnesses.

Jarrett Disbrow, President & CEO of Arbor said, “This new round of funding will allow the company to continue on its significant growth trajectory by introducing new and important treatment options for children.”

On the Web: www.arborpharma.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2009, TechJournal South. All rights reserved.